To Study the Effect Of Single Infusions Of Amphotericin B Lipid Preparations in Treatment of Patients Of Kala Azar

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-07-31

Study Completion Date

2011-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether a single bolus of dose of Amphoterin B lipid emulsion (Amphomul) is as efficacious and safe compared to a single dose Liposomal Amphotericin B in treating patients with Indian Visceral Leishmaniasis (Kala Azar).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar

NCT00497601

Visceral Leishmaniasis

COMPLETED PHASE2

Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis

NCT00628719

Visceral Leishmaniasis

COMPLETED PHASE3

Combination Chemotherapy for the Treatment of Indian Kala-Azar

NCT00370825

Visceral Leishmaniasis

COMPLETED PHASE2

Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar

NCT00371995

Visceral Leishmaniasis

COMPLETED PHASE2

Amphotericin B Treatment in Visceral Leishmaniasis

NCT00310505

Visceral Leishmaniasis

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Visceral Leishmaniasis, which is progressive and fatal if not treated, is an insidious, chronic disease that is characterized by irregular fever, anorexia, weight loss, cough, gross enlargement of the spleen and liver, mild anemia and emaciation. This may be preceded by rigors and vomiting. If untreated, Kala-azar, which is the most severe form of Leishmaniasis, has a mortality rate of nearly 100%.

The goal of the project is to establish that a single dose of AMPHOMUL® can be used to achieve a Definitive cure for Visceral Leishmaniasis leading to a short course therapy. The project will also seek to establish that AMPHOMUL ® is safe, at least as effective and more affordable than current treatment, and is without the risk of drug resistance.

The trial is a Prospective, Multicentric, Randomized, Two Arm, Open label Phase III study to Assess Efficacy and Safety of Infusion of Amphomul® (Amphotericin B Emulsion) as Compared to Liposomal Amphotericin B in Patients of Visceral Leishmaniasis (Kala azar)who are either treatment naive or treatment resistant to other antileishmanial drugs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Leishmaniasis, Visceral

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Amphotericin B lipid emulsion

Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A Drug: Amphotericin B lipid emulsion

Group Type EXPERIMENTAL

Amphotericin B Lipid emulsion

Intervention Type DRUG

Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis

Liposomal Amphotericin B

Liposomal Amphotericin B in visceral leishmaniasis - 15mg/kg on day 1 in Group B

Group Type ACTIVE_COMPARATOR

Liposomal Amphotericin B

Intervention Type DRUG

Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Amphotericin B Lipid emulsion

Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis

Intervention Type DRUG

Liposomal Amphotericin B

Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Amphomul AmBisome

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male or female patients aged between 5 to 65 years (both inclusive).
* Clinical signs and symptoms of Visceral Leishmaniasis (fever of over 2 weeks duration and splenomegaly)
* Presence of amastigotes (Leishmania-Donovani bodies) at prescreening detected by rK39 dipstick test with confirmation by splenic or bone marrow aspirate smear examination.
* Non-pregnant, non-lactating females of age ≥5 years, and woman of childbearing potential who are willing to use acceptable methods of contraception
* Negative Urine pregnancy test (UPT) in all women

Exclusion Criteria

* Patients with past history of treatment with Amphotericin B or any other drug for Visceral Leishmaniasis within 30 days prior to screening.
* Patients positive for HIV, HCV and HBsAg infection, immunocompromised patients (through history).
* Concurrent diabetes, tuberculosis or bacterial pneumonia or any other infectious or major psychiatric disease.
* Pregnant or nursing women
* Patients receiving any of the medications prohibited by the study protocol.
* Simultaneous participation in another trial or received any IP \<30 days prior to enrolment.

Minimum Eligible Age

5 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No